GO:0008641 ubiquitin-like modifier activating enzyme activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008641 describes the ATP-dependent activation of ubiquitin and ubiquitin-like proteins (UBLs) through formation of a high-energy thiolester bond, the first committed step in all UBL conjugation pathways.
• The reaction is catalyzed by E1 activating enzymes, which use ATP to adenylate the UBL C-terminus and then transfer it to an active-site cysteine, forming a covalent E1~UBL thiolester.
• UBL activating enzymes are not limited to ubiquitin: they include UBA1-UBA7 for ubiquitin, UBA2 (SUMO), UBA3 (NEDD8), UBA5 (UFM1), UBA6 (ubiquitin and FAT10), and UBA7 (ISG15).
• Dysregulation of UBL activation is linked to cancer, kidney fibrosis, neurodegeneration, and immune disorders, making these enzymes attractive drug targets.
• FAT10, a UBL, can stimulate deubiquitylating enzyme OTUB1 and interfere with SUMO activation, illustrating crosstalk between UBL pathways.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of UBL activating enzymes in disease and to validate inhibitors.
Description
Ubiquitin-like modifier activating enzyme activity (GO:0008641) is the molecular function that initiates the conjugation of ubiquitin and ubiquitin-like proteins (UBLs) to target substrates. This ATP-dependent process is catalyzed by E1 enzymes, which activate the UBL by forming a high-energy thiolester bond between a conserved active-site cysteine and the UBL C-terminus. The reaction is the first and rate-limiting step in all UBL conjugation cascades, including ubiquitination, SUMOylation, NEDDylation, UFMylation, FAT10ylation, and ISGylation. Because UBL modifications control protein stability, localization, and interactions, the activating enzymes are central regulators of cellular homeostasis and stress responses. Research into GO:0008641 has expanded beyond ubiquitin to include a family of UBLs such as SUMO, NEDD8, ISG15, FAT10, and UFM1. Each UBL has its own E1 activating enzyme, and some E1s, like UBA6, can activate more than one UBL. The specificity and regulation of these enzymes are critical for normal physiology; for example, UBA5 activates UFM1 and its inhibition is being explored for therapeutic benefit. Similarly, UBC9-associated SUMOylation, downstream of SUMO E1 activation, contributes to β-catenin activation and kidney fibrosis. These findings underscore the importance of GO:0008641 in both basic biology and disease. For researchers, GO:0008641 provides a functional annotation to study how cells control protein modification. Understanding the activation step helps explain how UBL pathways are initiated, how they are regulated, and how they can be targeted. This article reviews the mechanism, key genes, disease links, and experimental approaches for studying ubiquitin-like modifier activating enzyme activity.
ubiquitin-like modifier activating enzyme activity At A Glance
| GO ID | GO:0008641 |
|---|---|
| GO term | ubiquitin-like modifier activating enzyme activity |
| Ontology | molecular_function |
| Synonym | small protein activating enzyme activity |
| Major function | ATP-dependent activation of ubiquitin and ubiquitin-like proteins via thiolester bond formation |
| EC number | 6.2.1.- (acid-thiol ligases) |
| Representative enzymes | UBA1, UBA2, UBA3, UBA5, UBA6, UBA7 |
| Substrates | Ubiquitin, SUMO1-3, NEDD8, UFM1, FAT10, ISG15 |
| Pathway context | First step in ubiquitination, SUMOylation, NEDDylation, UFMylation, FAT10ylation, ISGylation |
What Is GO:0008641?
GO:0008641, ubiquitin-like modifier activating enzyme activity, is defined as the catalysis of the activation of small proteins, such as ubiquitin or ubiquitin-like proteins, through the formation of an ATP-dependent high-energy thiolester bond. In practice, this means an E1 enzyme binds a UBL and ATP, adenylates the UBL C-terminus, and then forms a covalent thiolester between the UBL and a cysteine residue in the E1 active site. This activated UBL is subsequently transferred to an E2 conjugating enzyme, marking the first step in UBL conjugation cascades.
Why Is ubiquitin-like modifier activating enzyme activity Important in Cell Biology?
Ubiquitin-like modifier activating enzyme activity is essential because it gates all downstream UBL conjugation events. Without activation, ubiquitin and UBLs cannot be transferred to E2 enzymes and ultimately to substrates, so processes such as proteasomal degradation, DNA repair, immune signaling, and stress responses would fail. Moreover, the activation step is a validated drug target: inhibitors of UBA5, for example, are being developed to modulate the UFMylation pathway. Thus, GO:0008641 is not only a fundamental molecular function but also a focal point for therapeutic intervention.
• Initiates all ubiquitin and UBL conjugation pathways, controlling protein stability and function.
• Regulates immune responses through ISG15 activation and MHC class I antigen presentation.
• Modulates SUMOylation, which affects transcription and fibrosis via β-catenin.
• FAT10 activation influences OTUB1 activity and SUMO crosstalk.
• UBA5-mediated UFM1 activation is a target for selective inhibitors.
• Dysregulation is implicated in cancer, kidney fibrosis, and neurodegeneration.
• Provides mechanistic insight into crosstalk between ubiquitin and UBL systems.
• Enables CRISPR-based functional studies of E1 enzymes in disease models.
Molecular Mechanism of ubiquitin-like modifier activating enzyme activity
ATP-dependent adenylation of the UBL
In simple terms: The enzyme first uses ATP to attach a small protein (UBL) to AMP, making it reactive.
The E1 activating enzyme binds a UBL and ATP, catalyzing the adenylation of the UBL C-terminal glycine. This step releases pyrophosphate and forms a UBL-AMP intermediate. This reaction is conserved across UBL systems and is the first committed step in activation.
Thiolester bond formation with the E1 active-site cysteine
In simple terms: The reactive UBL is then transferred to a cysteine in the enzyme, forming a high-energy bond.
The UBL-AMP intermediate reacts with a conserved cysteine residue in the E1 active site, forming a covalent thiolester bond between the UBL C-terminus and the enzyme. This E1~UBL thiolester is the activated form that can be transferred to an E2 enzyme. The high-energy bond drives downstream conjugation.
Transfer to E2 conjugating enzymes
In simple terms: The activated UBL is handed off to a second enzyme, E2, which continues the process.
The E1~UBL thiolester interacts with an E2 conjugating enzyme, and the UBL is transferred to the E2 active-site cysteine through a transthiolation reaction. This step is essential for subsequent substrate modification. E1 enzymes often interact with multiple E2s, providing specificity.
Crosstalk and regulation by UBLs
In simple terms: Different UBLs can influence each other's activation, adding layers of control.
FAT10, a UBL, can interfere with SUMO activation and stimulate the deubiquitylating enzyme OTUB1, demonstrating crosstalk between UBL pathways. Such interactions fine-tune the activation of UBLs and affect downstream signaling. This regulation is critical for cellular responses to stress and immune challenges.
Key Genes Involved in GO:0008641 ubiquitin-like modifier activating enzyme activity
The following genes encode E1 activating enzymes and related proteins that directly participate in or regulate ubiquitin-like modifier activating enzyme activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UBA1 | Activates ubiquitin for all ubiquitination pathways | Essential for proteostasis; mutations cause X-linked infantile spinal muscular atrophy |
| UBA2 | Activates SUMO1-3 | Key for SUMOylation; linked to cancer and fibrosis |
| UBA3 | Activates NEDD8 | Regulates cullin-RING ligases; target in cancer |
| UBA5 | Activates UFM1 | Inhibitors developed; role in ER stress and neurodegeneration |
| UBA6 | Activates ubiquitin and FAT10 | Unique dual specificity; involved in immune regulation |
| UBA7 | Activates ISG15 | Critical for antiviral and immune responses |
| UBC9 | E2 conjugating enzyme for SUMO | Downstream of SUMO E1; contributes to β-catenin activation |
| OTUB1 | Deubiquitylating enzyme | Stimulated by FAT10; regulates ubiquitin signaling |
| PRKN | E3 ubiquitin ligase | Deubiquitinated by USP33; role in mitophagy |
| USP33 | Deubiquitinase | Antagonizes PRKN/parkin in mitophagy |
| FAT10 | Ubiquitin-like modifier | Interferes with SUMO activation; stabilizes MYPT2 isoforms |
| MYPT2 | Protein phosphatase subunit | Differentially stabilized by FAT10 |
| ISG15 | Ubiquitin-like modifier | Involved in MHC class I antigen presentation |
| SUMO1 | Ubiquitin-like modifier | Activated by UBA2; regulates transcription and fibrosis |
| NEDD8 | Ubiquitin-like modifier | Activated by UBA3; controls cullin activity |
| UFM1 | Ubiquitin-like modifier | Activated by UBA5; ER stress response |
| β-catenin | Transcription co-activator | Activated by SUMOylation; drives kidney fibrosis |
How Is ubiquitin-like modifier activating enzyme activity Regulated?
The activity of ubiquitin-like modifier activating enzymes is regulated at multiple levels. UBL crosstalk, such as FAT10 interfering with SUMO activation, provides one layer of control. Deubiquitylating enzymes like OTUB1 can be stimulated by FAT10, affecting ubiquitin dynamics. Additionally, SUMOylation of β-catenin downstream of UBA2 activation contributes to kidney fibrosis, showing how activation is linked to pathological signaling. Inhibitors targeting UBA5 have been developed, demonstrating that pharmacological regulation is feasible.
ubiquitin-like modifier activating enzyme activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UBA2 | Kidney fibrosis via β-catenin SUMOylation | UBA2 knockout or knock-in in renal cells |
| UBA5 | Cancer and ER stress | UBA5 point-mutation or knockout cells treated with inhibitors |
| UBA7 | Immune response and antigen presentation | UBA7 knockout in antigen-presenting cells |
| UBA6 | FAT10-mediated immune regulation | UBA6 overexpression or knockout in immune cells |
| PRKN | Mitophagy and neurodegeneration | PRKN knockout or point-mutation neurons |
Cancer and fibrosis
Dysregulated UBL activation contributes to cancer and fibrosis. SUMOylation, initiated by UBA2, activates β-catenin and promotes kidney fibrosis. NEDDylation, via UBA3, regulates cullin-RING ligases that are often hijacked in cancer. Targeting UBA5 with selective inhibitors is a potential strategy for UFMylation-dependent cancers.
Neurodegeneration
Impaired ubiquitin activation and mitophagy are linked to neurodegeneration. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy, affecting neuronal survival. UBA5-mediated UFMylation is also implicated in ER stress responses relevant to neurodegeneration.
Immune and inflammatory disorders
ISG15 activation by UBA7 is important for antiviral responses and MHC class I antigen presentation. FAT10, activated by UBA6, modulates immune signaling and interferes with SUMO activation, linking UBL activation to inflammatory pathways.
From ubiquitin-like modifier activating enzyme activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does UBA5 loss affect UFMylation and cell survival? | UBA5 knockout cell line |
| Can a point mutation in UBA2 alter SUMOylation of β-catenin? | UBA2 point-mutation knock-in cells |
| How does FAT10 activation affect OTUB1 function? | FAT10 overexpression or knockout cells |
| What is the role of UBA7 in MHC class I presentation? | UBA7 knockout antigen-presenting cells |
| Does USP33 regulate PRKN stability? | USP33 knockout or overexpression in neurons |
| Can UBA5 inhibitors selectively kill cancer cells? | UBA5 knockout cells treated with inhibitors |
How to Study the ubiquitin-like modifier activating enzyme activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro thiolester assay | E1~UBL thiolester formation | Enzyme kinetics and inhibitor testing |
| Western blot for UBL conjugates | Global UBL conjugation levels | Knockout validation |
| Mass spectrometry | UBL-modified proteome | Pathway profiling |
| CRISPR knockout screen | Gene essentiality and drug sensitivity | Target discovery |
| Immunofluorescence | Localization of UBLs and E1s | Mitophagy and stress studies |
| Co-immunoprecipitation | E1-E2 interactions | Mechanistic studies |
| qPCR/RNA-seq | Transcriptional changes | Pathway analysis |
Biochemical assays for thiolester formation
In vitro assays using recombinant E1, UBL, ATP, and E2 can measure thiolester formation by gel shift or fluorescence. These assays directly assess GO:0008641 activity and are used to screen inhibitors.
Proteomics and ubiquitin/UBL profiling
Mass spectrometry-based proteomics can identify UBL-conjugated proteins and quantify changes upon E1 inhibition or knockout. This reveals downstream effects of altered activation.
CRISPR screening for pathway genes
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to UBL activation inhibitors or that synthetic-lethal with E1 loss. Such screens are powerful for discovering new regulators.
Imaging and cellular localization
Fluorescently tagged UBLs or E1 enzymes can be used to monitor activation and conjugation in live cells. This helps link GO:0008641 to specific cellular processes like mitophagy.
How CRISPR Can Be Used to Study GO:0008641 ubiquitin-like modifier activating enzyme activity
Knockout
CRISPR knockout of E1 genes such as UBA5 or UBA7 abolishes specific UBL activation, allowing researchers to study downstream effects. For example, UBA5 knockout cells show defective UFMylation and altered stress responses. UBA7 knockout impairs ISG15 conjugation and antigen presentation.
Point Mutation
Point mutations in the active-site cysteine of E1 enzymes can be introduced to specifically ablate catalytic activity without affecting protein stability. Such models help distinguish activation-dependent functions from scaffolding roles.
Knock-in
Knock-in of tagged or mutant E1 alleles enables precise tracking and functional analysis. For instance, tagging UBA2 with a fluorescent protein allows live-cell imaging of SUMO activation.
Overexpression
Overexpression of UBLs like FAT10 or E1 enzymes can amplify pathway activity and reveal crosstalk. FAT10 overexpression stimulates OTUB1 and interferes with SUMO activation, providing insights into UBL interplay.
How EDITGENE Supports ubiquitin-like modifier activating enzyme activity Research
Researchers studying ubiquitin-like modifier activating enzyme activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin-like modifier activating enzyme activity research.
Frequently Asked Questions About ubiquitin-like modifier activating enzyme activity
What is ubiquitin-like modifier activating enzyme activity?
It is the ATP-dependent activation of ubiquitin or ubiquitin-like proteins through formation of a high-energy thiolester bond, catalyzed by E1 enzymes.
What genes are involved in ubiquitin-like modifier activating enzyme activity?
Key genes include UBA1, UBA2, UBA3, UBA5, UBA6, and UBA7, each activating specific UBLs.
What is the GO ID for ubiquitin-like modifier activating enzyme activity?
The GO ID is GO:0008641.
How does UBA5 relate to UFMylation?
UBA5 is the E1 enzyme that activates UFM1, initiating UFMylation; its inhibitors are being developed.
What diseases are linked to UBL activating enzymes?
They are linked to cancer, kidney fibrosis, neurodegeneration, and immune disorders.
Can CRISPR be used to study UBL activating enzymes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used.
What is the role of FAT10 in UBL activation?
FAT10 can stimulate OTUB1 and interfere with SUMO activation, showing crosstalk.
How is SUMO activation involved in fibrosis?
SUMOylation via UBA2 activates β-catenin, contributing to kidney fibrosis.
What methods measure UBL activating enzyme activity?
In vitro thiolester assays, western blot, mass spectrometry, and CRISPR screens are common.
Are there inhibitors of UBL activating enzymes?
Yes, selective inhibitors of UBA5 have been discovered for the UFMylation pathway.
Conclusion
GO:0008641, ubiquitin-like modifier activating enzyme activity, is a fundamental molecular function that initiates all ubiquitin and UBL conjugation pathways. Its mechanisms, key enzymes, and disease links are well documented, and CRISPR-based models are indispensable for functional studies. Targeting these enzymes holds therapeutic promise, and continued research will uncover new regulatory layers and disease connections.
References
- 1. Bialas J et al.. 2019. The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1.. J Biol Chem 294(12):4315-4330 PMID: 30718280
- 2. Niu K et al.. 2020. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.. Autophagy 16(4):724-734 PMID: 31432739
- 4. Mignone JJ et al.. 2025. Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation Pathway.. J Med Chem 68(19):20827-20845 PMID: 40994290
- 5. Cai J et al.. 2025. UBC9-associated SUMOylation contributes to β-catenin activation and kidney fibrosis.. Kidney Int 108(4):642-657 PMID: 40712886
- 6. Held T et al.. 2021. Evidence for an involvement of the ubiquitin-like modifier ISG15 in MHC class I antigen presentation.. Eur J Immunol 51(1):138-150 PMID: 32686110
- 7. Aichem A et al.. 2019. The ubiquitin-like modifier FAT10 interferes with SUMO activation.. Nat Commun 10(1):4452 PMID: 31575873
- 8. Song SE et al.. 2023. FAT10 differentially stabilizes MYPT2 isoforms.. Biochem Biophys Res Commun 676:115-120 PMID: 37506472
